

12/07/99
JC714 U.S. PTO

12-08-99

BAKER & BOTTS, L.L.P.
30 ROCKEFELLER PLAZA
NEW YORK, NEW YORK 10112-0228

212 705-5000
FACSIMILE 212 705-5020

Appln. Trans.
PATENT

A

JC377 U.S. PTO
09/455952
12/07/99

UTILITY PATENT
APPLICATION
TRANSMITTAL

(Only for new nonprovisional
applications under 37 CFR 1.53(b))

Attorney Docket No. A32516

First Named Inventor Michalopoulos, G.

Express Mail Label No. EJ339569388US

December 7, 1999

BY EXPRESS MAIL - Label No. **EJ339569388US**

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

Sir:

Enclosed herewith for filing is a patent application of George Michalopoulos and William C. Bowen, citizens of the United States, whose post office addresses are 35 Highland Road, Apt. #6207, Bethal, PA 15102 and 1908 Dearborn Drive, White Oak, PA 15131 entitled :

"A NOVEL LONG-TERM THREE DIMENSIONAL TISSUE CULTURE SYSTEM"

which includes:

☒ Specification 35 Total Pages
☒ Claims 5 Total Pages
☒ Abstract 1 Total Pages
☒ Drawing(s) 16 Total Sheets
 formal informal

☒ Combined Declaration and Power of Attorney 3 Total Pages
 ☐ Newly executed (original or copy)
 ☐ Copy from a prior application
 (for continuation/divisional only - **must be filed to avoid surcharge for late filing**)

If a continuing application, check appropriate box:

☐ Continuation ☐ Divisional ☐ Continuation-In-Part (CIP)
 of prior application No.

☐ Amend the specification by inserting, before the first line, the following sentence:

"This is a ☐ continuation ☐ divisional ☐ continuation-in-part

Attorney Docket No. A32516

of copending application Serial No. _ filed _."

- ☐ An Assignment of the invention to _.
- ☐ is attached. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- ☐ will follow.
- ☐ has been filed in the prior application
- ☒ Small Entity Statement is attached.
- ☐ Small Entity Statement filed in prior application. Status still proper and desired.
- ☐ Information Disclosure Statement (IDS) PTO-1449
- ☐ Copies of IDS Citations.
- ☐ Preliminary Amendment
- ☒ Return Receipt Postcard
- ☐ Other _
- ☐ Cancel in this application original claims _ of the prior application before calculating the filing fee.

The filing fee has been calculated as shown below:

FOR	(Col. 1) <u>No. Filed</u>	(Col. 2) <u>No. Extra</u>	Small Entity <u>Rate</u>	<u>Fee</u>	OR	Other Than A Small Entity <u>Rate</u>	<u>Fee</u>
Basic Fee				\$380			
Total Claims	16	-20 = 0	x \$9 =	\$0		x \$18 =	
Ind. Claims	6	-3 = 3	x \$39 =	\$117		x \$78 =	
Multiple Dependent Claim			+ \$130 =	\$0		+\$260 =	
			Total	\$497			

* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

Fee Payment Being Made:

☒ Enclosed

☒ Basic filing fee

☐ Recording Assignment
[\$40.00; 37 CFR 1.21(h)]

Total Fees Enclosed \$497.00

Attorney Docket No. A32516

☒ A check in the amount of \$497.00 to cover the filing fee is enclosed.

Priority

☐ Priority of application Country __, Appln. No. __ filed __ is claimed under 35 U.S.C. 119.

☐ Certified Copy of Priority Document(s) Country __, Appln No. __, filed __.

☐ is/are attached ☐ will follow ☐ has been filed in the parent application S/N __.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR 1.16, 1.17, and 1.21(h) associated with this communication or credit any overpayment to Deposit Account No. 02-4377. Two copies of this sheet are enclosed.

BAKER & BOTTS, L.L.P.

By Carmella L. Stephens

Rochelle K. Seide

PTO Registration No. 32,300

Carmella L. Stephens

PTO Registration No. 41,328

Enclosures

BAKER & BOTTS, L.L.P.

30 ROCKEFELLER PLAZA

NEW YORK, NEW YORK 10112

TO ALL WHOM IT MAY CONCERN:

Be it known that WE, GEORGE MICHALOPOULOS and WILLIAM C. BOWEN, JR., citizens of the United States of America, whose post office addresses are 35 Highland Road, Apt. #6207, Bethel, PA 15102; and 1908 Dearborn Drive, White Oak, PA 15131, respectively, have invented an improvement in

A NOVEL LONG-TERM
THREE-DIMENSIONAL TISSUE CULTURE SYSTEM

of which the following is a

SPECIFICATION

1. INTRODUCTION

The present invention relates to a novel tissue culture system that provides for the long term culture of proliferating hepatocytes that retain hepatic function.

Disclosed are methods and compositions for *ex vivo* culturing of hepatocytes and nonparenchymal cells on a matrix coated with a molecule that promotes cell adhesion,

- 5 proliferation or survival, in the presence of growth factors, resulting in a long-term culture of proliferating hepatocytes that retain hepatic function. The co-culturing method results in the formation of matrix/hepatic cell clusters that may be mixed with a second structured or scaffold matrix that provides a three-dimensional structural support to form structures analogous to liver tissue counterparts. The hepatic cell culture system can be

ABSTRACT OF THE INVENTION

The present invention relates to a novel tissue culture system that provides for the long term culture of proliferating hepatocytes that retain hepatic function.

Disclosed are methods and compositions for *ex vivo* culturing of hepatocytes and nonparenchymal cells on a matrix coated with a molecule that promotes cell adhesion,

5 proliferation or survival, in the presence of growth factors, resulting in a long-term culture of proliferating hepatocytes that retain hepatic function. The co-culturing method results in the formation of matrix/hepatic cell clusters that may be mixed with a second structured or scaffold matrix that provides a three-dimensional structural support to form structures analogous to liver tissue counterparts. The hepatic cell culture system can be
10 used to form bio-artificial livers through which a subjects blood is perfused.

Alternatively, the novel hepatic cell culture system may be implanted into the body of a recipient host having a hepatic disorder. Such hepatic disorders, include, for example, cirrhosis of the liver, induced hepatitis, chronic hepatitis, primary sclerosing cholangitis and alpha₁ antitrypsin deficiency.

Applicant or Patentee: Michalopoulos, G. and Bowen, W.C.
Serial or Patent No.: TBA Filed or Issued: December 7, 1999
For: "A Novel Long-Term Three Dimensional Tissue Culture System"

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION University of Pittsburgh of the Commonwealth System of Higher Education

ADDRESS OF ORGANIZATION 200 Gardner Steel Conference Center, Pittsburgh, PA 15260

TYPE OF ORGANIZATION _____

- ☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE [26 USC 501(a) and 501(c)(3)]
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE ____)
(CITATION OF STATUTE ____)
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE ____)
(CITATION OF STATUTE ____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled _____ by inventor(s) _____ described in

- ☒ the specification filed herewith
☐ Application Serial No. __, filed __.
☐ Patent No. __, issued __.

I hereby declare that the rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(c) or by any concern which would not qualify as a

Attorney's Docket No. _____

small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e). *Note: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Frances J. ConnellTITLE IN ORGANIZATION Director, Office of Technology Transfer and Intellectual PropertyADDRESS OF PERSON SIGNING 200 Gardner Steel Conference Center, Pittsburgh, PA 15260SIGNATURE Frances J. Connell DATE _____

used to form bio-artificial livers through which a subjects blood is perfused.

Alternatively, the novel hepatic cell culture system may be implanted into the body of a recipient host having a hepatic disorder. Such hepatic disorders, include, for example, cirrhosis of the liver, induced hepatitis, chronic hepatitis, primary sclerosing cholangitis and alpha₁ antitrypsin deficiency.

The present invention is based on the discovery that mixed cultures of proliferating hepatocytes and nonparenchymal cells, grown on a collagen-coated matrix in medium containing hepatocyte growth factor (HGF) and epidermal growth factor (EGF), maintain their capacity to proliferate while retaining hepatic functions.

2. BACKGROUND OF INVENTION

One of the major functions of the liver is to break down harmful substances absorbed from the intestine or manufactured elsewhere in the body, followed by their excretion as harmless by-products into the bile or blood. Abnormalities of liver function caused by insult to and/or death or malfunction of the cells in the liver can lead to a variety of different hepatic disorders including cirrhosis of the liver or hepatitis.

Treatment of such disorders may include whole liver transplants, although this treatment is limited by organ availability, surgical complications, and immunologically-mediated graft rejection normally associated with liver transplantation.

While hepatocyte transplantation has been considered as an alternative to whole-organ transplantation, major technical barriers such as the inability to transfer donor hepatocytes into the liver of a recipient, in numbers to provide a beneficial result,

have limited the usefulness of this approach. One of the major difficulties in constructing artificial liver tissue is that, to function effectively, the artificial liver tissue requires functionally active, differentiated hepatocytes present at high densities. Future success with artificial liver tissue will depend on the development of systems in which

- 5 hepatocytes attached to matrices and packed at high density can retain long term their full functional capacity.

To generate artificial liver tissue, it will be necessary to provide *in vitro* cultures of hepatocytes. Unfortunately, one of the problems associated with the culturing of hepatocytes is that gene expression deteriorates rapidly as the hepatocytes proliferate.

- 10 Likewise, long-term cultures of hepatocytes having stable gene expression can only be maintained in the absence of cell proliferation. Thus, one of the long-standing goals of culturing hepatocytes is the establishment of proliferating cultures with long-term gene expression.

- A number of culture techniques have been developed that permit primary
- 15 hepatocyte cultures to grow and/or express complex patterns of hepatocyte differentiation (Mitaka, et al., 1995, *Biochem Biophys Res Commun* 214: 310-317; Cable, 1997, *Hepatology* 26: 1444-1445; Block, et al., 1996, *J. Cell Biol.* 132: 1133-1149). Conditions have also been established that allow mature hepatocytes to enter into clonal expansion in cell culture (Block, et al., 1996, *J. Cell Biol.* 132: 1133-1149). For example, hepatocytes
- 20 cultured in chemically defined hepatocyte growth medium (HGM) enter into DNA synthesis in response to polypeptide mitogens, notably epidermal growth factor (EGF), transforming growth factor- α (TGF- α), and hepatocyte growth factor (HGF). These

mitogens induce multiple rounds of DNA synthesis and expansion of the cell population. The proliferating cells, however, lose most markers of hepatocyte differentiation while they retain expression of hepatocyte associated transcription factors HNF1, HNF4, and HNF3. In addition, proliferation of adult hepatocytes has been observed in serum-free
 5 medium supplemented with nicotinamide and epidermal growth factor (EGF) (Mitaka, T., et al., 1991, *Hepatology* 12: 21-30; Mitaka, T., et al., 1992, *Hepatology* 10:440-447; Mitaka, T., et al., 1993, *J. Cell Physiol*, 147: 461-468; Mitaka, T., et al., *Cancer Res*, 1993, 53: 3145-3148; Block, G.D., et al., 1996, *J. Cell Biol.* 132:1133-1149; Tateno, C., et al., 1996, *Am J. Pathol* 148: 383-392).

10 Previous studies have indicated that a fundamental parameter that best determines hepatocyte gene expression in culture is the surrounding matrix. Hepatocytes embedded in complex matrices, such as Matrigel or type I collagen gels, maintain stable phenotypic expression, however, at the expense of cell proliferation. Recently, Mitaka, T. et al. (1999, *Hepatology* 29: 111-125) showed that small hepatocytes could
 15 differentiate to mature hepatocytes that interact with hepatic nonparenchymal cells and extracellular matrix. The mature hepatocytes reconstructed three-dimensional structures, expressed proteins known to be expressed in highly differentiated hepatocytes and the cells survived for more than 3 months, while maintaining hepatic differentiated functions. In addition, Landry et al. (1985, *J. Cell Biol.* 101:914-923) demonstrated the
 20 reconstruction of a three-dimensional cyto-architecture consisting of differentiated hepatocytes, bile duct-like cells and deposited extracellular matrix by the use of spheroidal aggregate culture of hepatic cells isolated from newborn rats. Three-

dimensional cell culture systems have also been disordered in which hepatocytes are grown on a pre-established stromal tissue (U.S. Patent No. 5,624,840). Attempts have also been made to grow a three-dimensional hepatic organoid using a co-culture of hepatocytes and fibroblasts (Senoo, et al., 1989, *Cell Biol. Internat. Reports* 13:197-206; Takezawa, et al., 1992, *J Cell Sci* 101:495-501).

A number of devices which perform the function of the liver and involve blood perfusion have been described (Hagger et al., 1983, *ASAIO J.* 6:26-35; U.S. Patent No. 5,043,260; U.S. Patent No. 5,270,192; Demetriou et al., 1986, *Ann. Surg* 9:259-271). However, a number of problems are associated with the use of such devices for treatment of patients suffering from hepatic failure or dysfunction. Perhaps, the most significant problem is the inability to culture hepatocytes that retain hepatic function for prolonged periods of time, although, attempts have been made to circumvent this problem through the use of transformed hepatocytes that are capable of proliferating indefinitely (U.S. Patent No. 4,853,324).

Development of a stable support system that would maintain hepatic functions and be useful in stabilizing patients in partial or complete hepatic failure has been a long-term scientific goal in the field of hepatology. Similar devices have revolutionized the treatment of patients with kidney failure and have allowed long-term stabilization of a large population of patients. Currently the use of such devices in treatment of liver failure is quite limited and existing devices are based on rapidly assembled hepatocyte support systems which partially sustain the patient over a very

limited period of time, *i.e.*, 24 to 48 hours with declining function over more prolonged term use.

3. SUMMARY OF THE INVENTION

The present invention relates to a novel tissue culture system that provides
 5 for long term culture of proliferating hepatocytes that retain their capacity to express
 hepatic function. The invention generally relates to compositions and methods for
 generating long term cultures of hepatocytes that can be used to produce three-
 dimensional hepatic cell culture systems. Such hepatic cell culture systems can be used
 to form bio-artificial livers that function as perfusion devices. Alternatively, the three-
 10 dimensional hepatic cell cultures may be implanted into a subject having a liver disorder.

The method of the present invention comprises the co-culturing of
 hepatocytes and nonparenchymal cells in the presence of growth factors and a matrix
 material coated with at least one biologically active molecule that promotes cell adhesion,
 proliferation or survival. The co-culturing method results in the formation of matrix/
 15 hepatic cell clusters containing a mixture of replicating hepatocytes and nonparenchymal
 cells. The method of the present invention may further comprise the mixing of the
 matrix/hepatic cell clusters in combination with a second structured, or scaffold matrix,
 that provides a three-dimensional structural support to form structures analogous to liver
 tissue counterparts.

20 Compositions of the present invention include populations of matrix/
 hepatic cell clusters comprising co-cultures of hepatocytes and nonparenchymal cells

bound to a matrix coated with at least one biologically active molecule that promotes cell adhesion, proliferation or survival. Further, the invention provides a three-dimensional hepatic cell matrix system comprising a three-dimensional support matrix containing a population of matrix/hepatic cell clusters comprising hepatocytes and nonparenchymal

5 cells bound to a matrix coated with at least one biologically active molecule that promotes cell adhesion, proliferation or survival.

The compositions of the present invention may be used to form bio-artificial livers through which a host's blood is perfused. Alternatively, the three-dimensional hepatic cell matrix system may be transplanted to a recipient host for
 10 providing hepatic function in subjects with liver disorders. The three-dimensional matrix system is administered in an effective amount to provide restoration of liver function, thereby alleviating the symptoms associated with liver disorders. The present invention, by enabling methods for generating long-term cultures of hepatocytes, provides a safer alternative to whole liver transplantation in subjects having liver disorders including, but
 15 not limited to, cirrhosis of the liver, alcohol induced hepatitis, chronic hepatitis, primary sclerosing cholangitis and α_1 -antitrypsin deficiency.

4. BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A-B. Thin sections of cells on beads in roller bottle cultures at day 15 after isolation, stained with toluidine blue.

20 Figure 1A. The bead is seen as a hollow space in the center of the cell cluster. Gray material around the bead represents dense type-1 collagen deposition. The

collagen surrounds and embeds connective-tissue derived nonparenchymal cells. Cells with hepatocyte morphology surround the connective tissue core.

Figure 1B. The epithelial cells with hepatocyte morphology form an eccentric growth over a foundation of connective tissue cells. Note the formation of multiple microvilli over the hepatocytes present on the surface.

Figure 2. Matrix deposition in Stage 1 roller bottle cultures. Panels A, B, and C show depositions of collagen types I, III, and IV, respectively. Collagen types I and III are deposited as broad bands surrounding the beads. Collagen type IV often formed basement membrane structures surrounding hepatocytes arranged in acinar or ductal configurations. Matrix is stained red whereas nuclei of the adjacent cells are stained blue. Visualization was by immunofluorescence microscopy.

Figure 3A-C. Electron microscopy of cultures at Stage 1 (Roller bottle).

Figure 3A. Low magnification view of hepatocytes growing on beads, before addition of Matrigel. Hepatocytes form a continuous multilayer or monolayer culture around the beads and display circuitous, interdigitated cell-cell contacts within the abluminal membrane. Canalicular structures (CC) and tight junctions (TJ) are seen. A 1-micron thick layer of fibrillar collagen (Col) is evident between the hepatocytes' abluminal membranes and the polystyrene bead. A nonparenchymal cell (NPC) is also seen within the fibrillar collagen layer. Bar = 1 mmol/L.

Figure 3B. Another view of the cytoplasmic features of hepatocytes at stage 1 (Magnification, 4,000X). Sinusoidal endothelial cells (SEC) are forming a layer of fenestrated endothelium. Fibrillar collagen (Col) and multiple microvilli are seen

under the endothelial layer, with a morphology similar to that seen in the space of Disse. Glycogen (Gly) and lamellae of rough endoplasmic reticulum (RER) are seen in the cytoplasm of the adjacent hepatocytes.

Figure 3C. Higher magnification of B (10,000X) showing the fenestrae of the endothelial layer. Collagen fibrils are seen in the interrupted cytoplasmic continuity of the endothelial cell at the site of the formation of the fenestra.

Figure 4A-C. Stains for macrophages, endothelial cells, and desmin-positive cells in Stage 1 roller bottle cultures. Visualization by differential interference microscopy. Positive immunohistochemistry is shown as red (complete arrows) whereas nuclei of cells are stained blue (truncated arrows).

Figure 4A. Macrophages staining positive for ED-1 antigen. Note the "foamy" cytoplasm characteristic of macrophages in some of the cells.

Figure 4B. Desmin-positive cells.

Figure 4C. Structures of endothelial cells staining positive for 1CAM1 antigen. One of the endothelial cells contains a nucleus at the field of the image (complete arrow).

Figure 5A-B. Migration of cell populations from bead clusters after placement in Matrigel (Collaborative Biomedical, MA). Phase contrast microscopy.

Figure 5A. Nonparenchymal cells (NP) migrate first and spread by attaching to the substratum. Occasional buddings of epithelial cells are seen at a higher focus plane (Hep). Some (arrow) appear to contain a duct. Culture at 1 week in Matrigel. Magnification, 200X.

Figure 5B. Multiple buddings of epithelial cells migrate out of the bead clusters at different planes and in all directions. Culture at 20 days in Matrigel. Magnification, 200X.

Figure 6. Histology of the epithelial cell buddings in Matrigel at Stage 2 cultures at day 20 in Matrigel. Epithelial cells with hepatocyte morphology (see Figure 8) are surrounding the central bead core and are arranged in sheets and ducts. Connective tissue deposition is also present underlying the epithelial cell structures. Hematoxylin eosin stain. Magnification, 200X.

Figure 7A. Low power electron micrograph of an acinar structure formed from the bead cluster. Evident are the duct-like canalicular structures (C) in the center of the acinar structure. Cells contain extensive RER and numerous mitochondria. A thick, but less electron dense layer of extracellular matrix than that observed for the pre-Matrigel bead is seen between the hepatocytes and the bead, with several fibroblastic (F) type cells residing in the matrix. Bar - 2 mm.

Figure 7B. High power micrograph of the canalicular structure seen in A. Readily obvious are three extensive tight junctional areas (TJ), desmosomes, RER, Golgi elements, and Mt, mitochondria. Bar = 500 nm.

Figure 8. Formation of plates by hepatocytes at Day 20 in Matrigel. Notice the prominent canalicular network (bright canals, arrows) along the middle of the plate.

Figure 9. Cellular and matrix immunohistochemistry in Stage 2 cultures in Matrigel. Staining by immunoperoxidase. Panels A,B,C, and D show stains for

desmin, Collagen types I, III, and IV, respectively. Desmin-positive stellate cells are interspersed in close proximity to the hepatocytes. Collagen type III shows the strongest immunohistochemical response. Collagen type IV often formed basement membrane structures surrounding hepatocytes arranged in acinar or ductal configurations (arrow).

5 Figure 10A Phase contrast microscopy of monolayers developing at 2 to 3 months in Matrigel (Stage 3 cultures) in the presence of HGF and EGF. Magnification 100X.

10 Figure 10B. Magnification 200X. Notice the extensive canalicular network (bright lines ramifying with short branches along the hepatocyte plates), the pseudo-sinusoidal spaces (S), and the duct-like structures (D).

 Figure 11A. A low power (2,000X) electron micrograph of hepatocytes in Stage 3 cultures. Notice the longitudinal section of the extensive canalicular network (with microvilli and desmosomes) surrounding the individual hepatocytes.

15 Figure 11B. Higher power view (10,000X) showing detailed cytoplasmic features. Rough endoplasmic reticulum, mitochondria, and Golgi network elements are seen in the individual hepatocytes.

20 Figure 12. Expression of several genes in hepatocytes immediately after isolation (Time zero), cells in roller bottle at day 13, cells in roller bottle at day 25, cells in Matrigel (Collaborative Research) cultures at day 25 (12 days after placement in Matrigel at Day 13), and nonparenchymal hepatic cell fraction (5% nonparenchymal hepatocyte contamination) immediately after isolation. Expression of GAPDH is used as a normalizing parameter.

Figure 13A-C. Induction of the cytochrome P450 species CYP3A

(Figure 13A), CYP1A (Figure 13 B) and CYP2B1/2 (Figure 13C) by their characteristic inducers in day 35 cultures. The increase in actual is demonstrated by western immunoblot. C stands for control. Dex (dexamethasone); 3MC (3' Methylcholanthrene); PB (Phenobarbital) were the inducers used correspondingly.

Figure 14. Enzymatic Activities. The activities of testosterone 6 β -hydroxylase (CYP3A dependent) and ethoxyresorufin O-deethylase (CYP1A dependent) were also measured in the same cultures. As demonstrated, more than 20-fold induction was seen in both cases by the characteristic inducers.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a novel tissue culture system that provides for long term culture of hepatocytes that retain their capacity to proliferate and express hepatic function. The invention provides compositions and methods for generating long term cultures of hepatocytes that can be used as bio-artificial livers for perfusion purposes. Alternatively, the hepatic cell culture systems may be implanted into a subject having a hepatic disorder to restore or supplement liver function.

The method of the present invention comprises the co-culturing of hepatocytes and nonparenchymal cells, in the presence of growth factors and a matrix material coated with at least one biologically active capable of a molecule promoting cell adhesion, proliferation or survival, thereby, resulting in the formation of matrix/hepatic cell clusters. The method of the present invention may further comprise the mixing of the

matrix/hepatic cell clusters with a second matrix material that provides a three-dimensional structural support to form structures analogous to liver tissue found *in vivo*.

The compositions of the present invention include matrix/ hepatic cell cultures comprising hepatocytes that retain their capacity to proliferate while expressing
 5 hepatic function. Further, the invention provides a three-dimensional hepatic cell culture system comprising hepatic cells that retain their capacity to proliferate and express hepatic function growing in a three-dimensional structure .

The hepatic cell system can be used for generating bio-artificial livers that function as perfusion devices for restoration of liver function. The three-dimensional
 10 matrix hepatic cell system can be administered to an individual for providing hepatic function in subjects with liver disorders. The matrix/hepatic cell system is administered in an effective amount necessary for restoration of liver function, thereby alleviating the symptoms associated with liver disorders.

15 5.1. MIXED CULTURES OF HEPATOCYTES AND NONPARENCHYMAL CELLS

The present invention relates to methods for generating long term cultures of proliferating hepatocytes that retain their hepatic function. The method generally comprises co-culturing or propagating hepatocytes and nonparenchymal cells on a matrix
 20 coated with a biologically active molecule that promotes cell adhesion, *in vitro*. The cells are cultured under conditions effective and for a time sufficient to allow formation of a culture of proliferating hepatocytes that retain hepatic function. The cells are grown in

the presence of growth factors that maintain hepatic cell differentiation and the capacity to proliferate.

Hepatocytes and nonparenchymal cells may be obtained from a variety of different donor sources. In a preferred embodiment, autologous cells are obtained from the subject who is to utilize the bio-artificial liver or receive the transplanted hepatic cells to avoid immunological rejection of foreign tissue. In yet another preferred embodiment of the invention, allogenic liver tissue for use in purifying cells may be obtained from donors who are genetically related to the recipient and share the same transplantation antigens on the surface of their hepatic cells. Alternatively, if a sibling is unavailable, tissue may be derived from antigenically matched (identified through a national registry) donors.

In an embodiment of the invention, hepatic cells and nonparenchymal cells are isolated from a disaggregated liver tissue biopsy. This may be readily accomplished using techniques known to those skilled in the art. For example, the liver tissue can be disaggregated mechanically and/or treated with digestive enzymes and/or chelating agents that weaken the connections between neighboring cells, making it possible to disperse the tissue suspension of individual cells. Enzymatic dissociation can be carried out by mincing the liver tissue and treating the minced tissue with any of a number of digestive enzymes. Such enzymes include, but are not limited to, trypsin, chymotrypsin, collagenase, elastase and/or hylauronidase. A review of tissue disaggregation techniques is provided in, *e.g.*, Freshney, Culture of Animal Cells, A Manual of Basic Technique, 2d Ed., A.R. Liss, Inc., New York, 1987, Ch. 9, pp.107-126. In addition to primary cell

cultures, established hepatic cell lines may also be utilized in the methods and compositions of the invention.

The present methods and compositions can also employ hepatic cells genetically engineered to enable them to produce a wide range of functionally active biologically active proteins, including but not limited to growth factors, cytokines, hormones, inhibitors of cytokines, peptide growth and differentiation factors. Additionally, the cells may be genetically engineered to increase their proliferative capacity, *i.e.*, the cells may be immortalized. Methods which are well known to those skilled in the art can be used to construct expression vectors containing a nucleic acid encoding the protein coding region of interest operatively linked to appropriate transcriptional/translational control signals. See, for example, the techniques described in Sambrook, et al., 1992, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., and Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates & Wiley Interscience, N.Y., incorporated herein by reference.

Once isolated, the hepatic and nonparenchymal cells can be grown in any culture medium known to those skilled in the art to support the growth and proliferation of such cells. For example, the mixed cultures of cells can be grown in chemically defined hepatocyte growth medium (HGM) supplemented with specific growth factors and regulatory factors. Such factors can be added to the culture media to enhance, alter or modulate proliferation and/or differentiation of the cultured hepatocytes and nonparenchymal cells. In a preferred embodiment of the invention, the culture media

may be supplemented with growth factors such as hepatocyte growth factor (HGF) and/or epidermal growth factor (EGF), or functional homologs thereof, to impart phenotypic stability in terms of differentiated hepatocyte gene expression and the ability to proliferate.

5 In addition, the co-cultures of cells are propagated in the presence of a natural or synthetic matrix that provides support for hepatic cell growth during *in vitro* culturing. The type of matrix that may be used in the practice of the invention is virtually limitless. The matrix will have all the features commonly associated with being “biocompatible”, in that it is in a form that does not produce an adverse, or allergic
10 reaction when administered to the recipient host. In a preferred embodiment of the invention, the matrix is in the form of a bead to which the cultured cells may adhere. The beads may be composed of variety of different substances including, but not limited to, synthetic materials or naturally derived materials. The type of matrix material to be used will depend on the desired use of the hepatocyte cultures. For example, when the
15 matrices are to be transplanted into a subject it is preferred that a biodegradable matrix material be used. For purposes of forming bio-artificial livers, the matrix may be composed of any suitable material to which the hepatocytes and nonparenchymal cells will adhere and proliferate.

 Further, to improve hepatic cell adhesion, proliferation or survival, the
20 matrix is coated on its external surface with factors known in the art to promote cell adhesion, growth or survival. Such factors include cell adhesion molecules, extra-cellular matrix molecules and/or growth factors for hepatocytes and/or nonparenchymal cells.

Matrices may also be designed to allow for sustained release of growth factors over prolonged periods of time. Thus, appropriate matrices will ideally provide factors known to promote hepatic cell adhesion, growth or survival, and also act as a support on which the cultured cells differentiate and proliferate. In a preferred embodiment of the invention, the hepatic cell cultures are propagated in media containing matrices coated with collagen type I protein for promotion of cell adhesion and proliferation of bound hepatocytes.

The method of the present invention involves the co-culturing of hepatic and nonparenchymal cells in the presence of the selected matrix material. Although the cells may be propagated under static conditions, it is preferred that the cells are propagated under mixing or stirring conditions wherein a cell suspension is combined with matrix, and mixed or stirred, to enhance the number and frequency of cell contacts with the matrix to maximize cell adhesion to the matrix, but not disrupt adherence to cells. Such conditions may be generated in variety of different ways including, for example, the use of roller bottles to provide continuous stirring or mixing of the culture. Preferably, the stirring is continued throughout the culturing of the hepatic and nonparenchymal cells.

The conditions of long-term matrix-cell culturing will preferably be maximized to enhance hepatocyte proliferation while maintaining hepatic function.

Although certain variations in cell number, seeding techniques, culture media, incubation temperatures and incubation times, may be utilized, such variations would be routine to those skilled in the art and are encompassed by the present invention.

5.2. PREPARATION OF THREE-DIMENSIONAL CULTURE SYSTEMS

The present invention further relates to the use of the matrix/hepatic/nonparenchymal cell clusters, produced as described in Section 5.1, for generation of three-dimensional hepatic cell culture systems to form structures analogous to liver tissue counterparts. The method of the invention comprises growing hepatic and nonparenchymal cells on a three-dimensional matrix *in vitro* under conditions effective and for a period of time sufficient to allow proliferation of the cells to form a three-dimensional structure.

The three-dimensional matrices to be used are structural matrices that provide a scaffold for the cells, to guide the process of tissue formation. Cells cultured on a three-dimensional matrix will grow in multiple layers to develop organotypic structures occurring in three dimensions such as ducts, plates, and spaces between plates that resemble sinusoidal areas, thereby forming new liver tissue. Thus, in preferred aspects, the present invention provides a three-dimensional, multi-layer cell and tissue culture system. The resulting liver tissue culture system survives for prolonged periods of time and performs liver-specific functions for use as a perfusion device or following transplantation into the recipient host.

A wide variety of structural matrices may be used in the context of the present invention for preparation of a three-dimensional hepatic cell culture system. In preferred embodiments, the matrices are bio-compatible matrices that provide a scaffold for the cells to guide the development of tissue. Preferred matrices are generally those that define a space for subsequent tissue development. Such matrices include hydrogels,

biomatrix gels, or porous materials such as fiber based or sponge like matrices. The culture system described herein provides for the proliferation of cells to form structures analogous to liver tissue counterparts *in vivo*.

In certain embodiments, synthetic matrices, such as synthetic polymer
 5 matrices, may be used. Such matrices include, but are not limited to, nylon, dacron, polystyrene and homopolymers or heteropolymers such as polylactic acid (PLA) polymers, polyglycolic acid (PGA) polymers and polylactic acid-polyglycolic acid (PLGA) copolymer matrices. In other embodiments, matrices for use in the invention may be naturally-derived matrices extracted from or resembling extracellular matrix materials
 10 such as a collagen matrix, such as type I collagen. Other naturally derived matrix materials include laminin-rich gels, alginate, agarose and other polysaccharides, gelatin and hyaluronic acid derivatives. Certain matrix materials may not support efficient cellular attachment and, in such instances, it may be advantageous to coat the matrix with molecules that promote cell adhesion, such as extracellular matrix proteins or,
 15 specifically, collagen type I.

To generate the three-dimensional hepatic cell cultures, matrix/hepatic/nonparenchymal cell clusters generated as described above in Section 5.1 are isolated from cell culture suspensions. For example, the cell clusters may be isolated by low speed gravity sedimentation. The matrix/hepatic/nonparenchymal cell clusters are then
 20 exposed to a second structural matrix material in the presence of an appropriate culture media, thereby providing an environment for three-dimensional hepatic cell growth. Many commercially available culture media, supplemented in some instances with

growth factors and the like, may be suitable for use. In addition, the culture media may be replenished periodically to provide a fresh supply of nutrients. The three-dimensional hepatic cell culture system is cultured for a sufficiently long period of time to allow the hepatic cells to replicate to form a three-dimensional cell or tissue structure.

5 Prior to use of three-dimensional hepatic cell cultures, the cultures may be contacted with a number of different growth factors that can regulate tissue regeneration by affecting cell proliferation, and gene expression. Such growth factors include those capable of stimulating the proliferation and/or differentiation of hepatic progenitor cells. For example, epidermal growth factor (EGF), transforming growth factor α (TGF- α) or
10 hepatocyte growth factor (HGF) may be utilized. The hepatic cells may be stimulated *in vitro* prior to transplantation into the recipient subject, or alternatively, by injecting the recipient with growth factors following transplantation.

5.3. USE OF THE HEPATIC CELL CULTURES

The hepatic cell cultures of the invention can be used as bio-artificial
15 livers for use by subjects having liver disorders that result in hepatic failure or insufficiency. The use of such bio-artificial livers involves the perfusion of the subject's blood through the bio-artificial liver. In the blood perfusion protocol, the subject's blood is withdrawn and passes into contact with the hepatocyte cell cultures. During such
20 passage, molecules dissolved in the patient's blood, such as bilirubin, are taken up and metabolized by the hepatocyte cultures. In addition, the cultured hepatocytes provide factors normally supplied by liver tissue.

To form the bio-artificial liver the three-dimensional hepatocyte cell cultures of the invention are grown within a containment vessel containing an input and output outlet for passage of the subjects blood through the containment vessel. The bio-artificial liver further includes a blood input line which is operatively coupled to a

5 conventional peristaltic pump. A blood output line is also included. Input and output lines are connected to appropriate arterial-venous fistulas which are implanted into, for example, the forearm of a subject. In addition, the containment vessel may contain input and output outlets for circulation of appropriate growth medium to the hepatocytes for continuous cell culture within the containment vessel.

10 In an embodiment of the invention, semipermeable membranes may be included in the bio-artificial livers to prevent direct contact of the subject's blood with the three-dimensional hepatocyte cultures. In such instances, the molecules dissolved in the subject's blood will diffuse through the semipermeable membrane and are taken up and metabolized by the hepatocyte cultures.

15 The use of the cultured hepatocyte systems of the invention to form bio-artificial livers provides a method which may be utilized to provide liver function to subjects suffering from hepatic failure or insufficiency.

The three-dimensional hepatic cell cultures can also be administered or transplanted to the recipient in an effective amount to achieve restoration of liver

20 function, thereby alleviating the symptoms associated with liver disorders. When the hepatic cell cultures are to be administered to a recipient, it is desirable to form the

hepatocyte cultures with hepatocytes and nonparenchymal cells derived from the recipient so as to avoid tissue rejection.

5 The number of cells needed to achieve the purposes of the present invention will vary depending on the degree of liver damage and the size, age and weight of the host. For example, the cells are administered in an amount effective to restore liver function. Determination of effective amounts is well within the capability of those skilled in the art. The effective dose may be determined by using a variety of different assays designed to detect restoration of liver function. The progress of the transplant recipient can be determined using assays that include blood tests known as liver function tests. Such liver function tests include assays for alkaline phosphatase, alanine transaminase, aspartate transaminase and bilirubin. In addition, recipients can be examined for presence or disappearance of features normally associated with liver disease such as, for example, jaundice, anemia, leukopenia, thrombocytopenia, increased heart rate, and high levels of insulin. Further, imaging tests such as ultrasound, computer assisted tomography (CAT) and magnetic resonance (MR) may be used to assay for liver function.

10 The three-dimensional hepatic cell system can be administered by conventional techniques such as injection of cells into the recipient host liver, injection into the portal vein, or surgical transplantation of cells into the recipient host liver. In some instances it may be necessary to administer the hepatic cell composition more than once to restore liver function. In addition, growth factors, such as G-CSF, or hormones, may be administered to the recipient prior to and following transplantation for the

purpose of priming the recipients liver and blood to accept the transplanted cells and/or to generate an environment supportive of hepatic cell proliferation.

6. EXAMPLE: MIXED CULTURES OF HEPATOCYTES AND NONPARENCHYMAL CELLS MAINTAINED IN BIOLOGICAL MATRICES

The purpose of the present example is the demonstration that mixed cultures of hepatocytes and nonparenchymal cells grown in chemically defined hepatocyte growth medium (HGM) containing hepatocyte growth factor and epidermal growth factor on collagen-coated polystyrene beads retain their hepatic functions while maintaining their capacity to proliferate.

6.1. MATERIALS AND METHODS

6.1.1 ANIMALS

Male Fischer 344 rats from Charles River were used for the studies described.

6.1.2 REAGENTS

EGF was obtained from Collaborative Biomedical (Waltham, MA). Collagenase for hepatocyte isolation was obtained from Boehringer Mannheim (Mannheim, Germany). Vitrogen (Celtrix Labs., Palo Alto, CA) was used for the construction of the collagen gels. General reagents were obtained from Sigma (St. Louis, MO). EGF and Matrigel (Collaborative Research) were purchased from Collaborative Biomedical (Waltham, MA). HGF used for these studies was the $\Delta 5$ variant and was

kindly donated by Snow Brand. (Toshigi, Japan). Polystyrene beads coated with type I collagen were purchased from SoloHill Inc. (Ann Arbor, MI). Antibody sources: Mouse anti-rat ICAM (CD54) Pharmingen (San Diego, CA) (1:500); rabbit anti-rat collagen I, Chemicon (Temecula, CA) (1:100); rabbit anti-rat collagen III, Chemicon (1:100); Mouse anti-desmin, Dako (Carpenteria, CA) (1:100); Mouse anti-rat monocyte/macrophage (ED-1) Serotec (Raleigh, NC) (1:500); Rabbit anti-rat Collagen IV, gift from Dr. A. Martinez-Hernandez (1:100).

6.1.3 ISOLATION AND CULTURE OF HEPATOCYTES

Rat hepatocytes were isolated by an adaptation of Seglen's calcium two-step collagenase perfusion technique (Seglen, P.O., 1976, *Methods in Cell Biol.* 13:29-83) as previously described (Kost, DP et al., 1991, *J. Cell Physiol.* 147:274-289). Typically, a 3% contamination with nonparenchymal cells is seen in this isolate.

The nonparenchymal cell fraction was defined as the cell pellet isolated from the supernatant of the first low-gravity centrifugation used to prepare hepatocytes.

This fraction primarily contains cells of Ito, bile duct cells, and endothelial cells. Small hepatocytes are also present in this fraction, typically comprising 5% of the cells.

6.1.4 ROLLER BOTTLE CULTURES

Freshly isolated hepatocytes were added to roller bottles (850 cm² surface) obtained from Falcon (Franklin Lakes, NJ). Each bottle contained 18.7×10^6 polystyrene beads and 210×10^6 freshly isolated hepatocytes in 250 mL of HGM medium

supplemented with HGF (20 ng/mL) and EGF (10 ng/mL). The bottles were rotated at a rate of 2.5 rotations per minute and kept in an incubator maintained at 37°C, saturated humidity, and 5% CO₂. The viability of the cultures was assessed by periodic sampling. The samples were directly observed under a phase contrast microscope as well as stained
 5 with methyl tetrazolium to assess viability.

6.1.5 CULTURES OF BEADS IN MATRIGEL

The bead clusters containing cells were isolated from suspensions obtained from the roller bottle cultures. Enrichment for clusters was obtained by allowing for 2 minutes of unit gravity sedimentation. The bead and cell clusters were mixed with
 10 Matrigel (Collaborative Research). Bead clusters with attached cells were allowed to settle whereas beads without cells stayed mostly in suspension. The supernatant was aspirated leaving the clusters in the bottom of the tube. The process was repeated three times. Clusters suspended in medium were mixed with Matrigel at a volume ratio of 1:4 (medium plus beads: Matrigel). Approximately 50 to 100 bead clusters were randomly
 15 embedded in Matrigel.

6.1.6 COMPOSITION OF THE HGM

HGM was prepared as previously described (Block, G.D. et al., 1996, *J Cell Biology* 132:1133-1149). DMEM medium powder, HEPES, glutamine, and antibiotics were purchased from GIBCO/BRL (Grand Island, NY). ITS mixture (Insulin,
 20 Transferrin, Selenium) was purchased from Boehringer Mannheim. All other additives

were cell-culture grade (Sigma). Unless otherwise indicated for specific experiments, the basal HGM consisted of DMEM supplemented with purified bovine albumin (2.0 g/L), glucose (2.0 g/L), galactose (2.0 g/L), ornithine (0.1 g/L), proline (0.030 g/L), nicotinamide (0.305 g/L), ZnCl_2 (0.544 mg/L), $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ (0.750 mg/L), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.20 mg/L), MnSO_4 (0.025 mg/L), glutamine (5.0 mmol/L), and dexamethasone (10^{-7} mol/L). Penicillin and streptomycin were added to the basal HGM at 100 Mg:/L and 100 µg/L, respectively. The mixed basal HGM was sterilized by filtration through a 0.22-µm low-protein—binding filter system, stored at 4°C, and used within 4 weeks. ITS 1.0 g/L, (right hip-insulin 5.0 mg/L, human transferrin 5.0 mg/L [30% diferric iron saturated]), selenium 5.0 µg/L) was added after filtration immediately before use. The growth factors, as required, were added to HGM fresh at the specified concentrations every time the medium was changed.

6.1.7 TRANSMISSION ELECTRON MICROSCOPY

Samples for transmission electron microscopy were washed once in PBS with 1 mmol/L MgCl_2 , 0.5 mmol/L CaCl_2 , then fixed overnight at 4°C in 2.5% glutaraldehyde in PBS. Samples were washed three times with PBS then postfixes in 1% OsO_4 , 1% $\text{KFe}(\text{CN})_6$ in PBS for 1 hour at room temperature. Samples were washed three times in PBS, then dehydrated through graded series (30%-100%) of ethanol. Following three changes of 100% ethanol, samples were infiltrated with several changes of Polybed 812 resin (Polysciences, Warrington, PA) at room temperature, a change overnight at 4°C, then a final change, in the case of cells grown on monolayers, where Beem capsules,

filled with resin, were inserted on top of areas of interest. Resin was hardened overnight at 37°C, then for 2 additional days at 65°C. While the resin was still warm, Beem capsules were pulled from the dish and analyzed to ensure that the cells did not remain on the dish. In some cases monolayers were re-embedded to obtain cross sections. Thick sections (300 µm), obtained using a Reichert (Vienna, Austria) ultramicrotome fitted with a diamond knife, were heated onto glass slides, stained with 1% Toluidine Blue, and rinsed with water. Ultra thin sections (60 nm) were collected on Formvar-coated (Fullam, Schenectady, N.Y.) grids and stained with 2% uranyl acetate in 50% methanol for 10 minutes, then 1% lead citrate for 7 minutes. Sections were analyzed and photographed on a JEOL JEM 1210 transmission electron microscope at 80 kV.

6.1.8 IMMUNOFLUORESCENCE MICROSCOPY

Samples from roller-bottle cultures were fixed in 2% paraformaldehyde and 0.01% glutaraldehyde in PBS for 1 hour. Liver seeds were then stabilized by dipping them in 3% gelatin in PBS, then refixing them in the above fixative for an additional 15 minutes. Samples were incubated in 2.3 mol/L sucrose in PBS at 4°C overnight. Samples were mounted on screw stubs and snap-frozen in liquid nitrogen. Five hundred nanometer-thick frozen sections were cut on a FCS Ultracut Microtome (Reichert) fitted with a cryokit. Sections were attached to glass slides by adsorbed Cell-Tak (Collaborative Biomedical). Sections were washed in 0.5% BSA, 0.15% glycine in PBS (PBG buffer) three times to remove sucrose, then blocked with 5% goat serum in PBG buffer for 30 minutes. Sections were then stained with various antibodies in PBG buffer

for 1 hour at room temperature, washed three times in PBG buffer then stained with Cy3-conjugated (goat antirabbit or antimouse) secondary antibodies (Jackson Immunolabs, Bar Harbor, ME) for 1 hour. Sections were washed three times with PBG buffer, then once in PBS. Nuclei were stained with 0.1 mg/mL Hoechst (bisBenzimide) for 30 seconds, washed twice with PBS, then mounted on slides with use of gelvatol (23 g polyvinyl alcohol 2000, 50 mL glycerol, 0.1% sodium azide to 100 mL PBS), and viewed on an Olympus Provis epifluorescence microscope (Olympus America, Melville, N.Y.) also equipped for differential interference microscopy.

6.1.9 ANALYSIS OF GENE EXPRESSION BY NORTHERN BLOTS

Total RNA was extracted by use of RNazol B® (Biotechx, Houston, TX). RNA extraction from roller-bottle cultures was performed by washing bead-cell clusters in phosphate buffered saline and further digestion of the clusters by adding an equal volume of Trypsin-Ethylenediaminetetraacetic acid (GIBCO-BRL) to the bead-cell suspension. The mixture was shaken at 37°C for 10 minutes. The bead-cell clusters were further washed in S+M buffer at 4°C three times. The bead-cell pellet was mixed with three volumes of RNazol and purified according to the manufacturer's guidelines.

RNA was extracted from Matrigel (Collaborative Research) -embedded beads by vortexing using 2.0 mL of RNazol B® (Biotechx) per 1 mL of beads in Matrigel and purified per the manufacturer's guidelines. RNA concentration and purity were determined routine spectrophotometry. Size separation of 20 µg RNA per lane was completed on denaturing 1% agarose gels and transferred to nylon membranes

(Amersham, Piscataway, N.J.) by the capillary method. After cross-linking under ultraviolet light, membranes were hybridized overnight with specific complementary DNAs (as indicated in Figure 12) that had been labeled with [α - 32 P]dCTP using Amersham random primer kit. Membranes were subsequently washed under high stringency conditions and exposed to R film (photographic film) (Kodak, N.Y.) for 1 to 3 days. Quantification of the RNA hybridization bands was performed by laser densitomer.

6.1.10 SOURCES OF COMPLEMENTARY DNA PROBES

EGF-R (rat) was obtained from Dr. Sheldon Earp, University North Carolina at Chapel Hill; acidic fibroblast growth factor receptor from American Type Culture Collection (catalog number 78222); acidic fibroblast growth factor receptor from American Type Culture Collection (catalog number 65796); urokinase plasminogen activator originated from Dr. Jay Degen, University of Cincinnati; cytochrome IIB1 from Dr. Steve Strom (University of Pittsburgh); complementary DNAs for albumin, α -fetoprotein were generated by Dr. Joe Locker (University of Pittsburgh).

6.2. RESULTS

6.2.1 MORPHOGENETIC EVENTS IN CULTURES OF DIFFERENT STAGES

Stage 1: Cultures of Hepatocytes on Beads in Roller Bottles. Collagen-coated polystyrene beads, were placed in roller bottles at a ratio of 18.7×10^6 beads to 210×10^6 freshly isolated hepatocytes. HGF and EGF were added as standard

supplements in the HGM medium of the roller bottle cultures. Cells attached to the beads and, within 2 to 3 weeks, formed clusters of beads bound together with mesenchymal cells surrounded by layers of epithelial cells. The mesenchymal cells concentrate toward the center of the cluster and surround the individual beads (Figure 1A and 1B). They are associated with heavy deposition of type I and type III collagen immediately against the surface of the bead (Figure 2). The collagen bundles surround the mesenchymal cells. Collagen type IV was seen as a thin rim forming a basement membrane surrounding only acinar structures of epithelial cells. The epithelial cells grow outside of the mesenchymal cells and symmetrically surround the beads or make eccentric projections. The epithelial cells have characteristics of small mature hepatocytes, as shown by electron microscopy. They contain multiple mitochondria and minimal rough endoplasmic reticulum (Figure 3). Mature bile canaliculi containing microvilli as defined by junctional complexes were occasionally seen. Most often, they appeared as spaces surrounded by hepatocytes and containing microvilli. The junctional complexes were not as clearly defined as after placement in Matrigel (Collaborative Research). Those cells that are on the surface of the clusters have visible microvilli, whereas those toward the interior do not. The epithelial cells form multiple cell layers from the mesenchymal cell layer of the cluster to the surface. The cytoplasmic details of the epithelial cells in the clusters are shown in Figure 3B and 3C. Multiple lamellae of rough endoplasmic reticulum and glycogen deposition is seen. Notable is the occasional information of fenestrated endothelium surrounding the hepatocytes. The proliferating cellular nuclear antigen (PCNA) labeling index of the epithelial cells exceeded 70% in all clusters. The BRdU labeling index of epithelial cells

varied from 10% to 15% in different clusters. The number of nonparenchymal cells varied from one cluster to another. Figure 4 shows desmin-positive mesenchymal cells, presumably derived from stellate cells contaminating the original hepatocyte preparation, interspersed between the epithelial cells. Approximately 15% to 20% of the cells at this stage seem to belong to this category. ICAM1-positive endothelial cells are also seen in Figure 4, occasionally forming ICAM1-positive luminal structures. Overall, less than 2% of the cells at this stage stained positive for this antibody. Macrophages, identified as ED-1-positive cells, are seen only in sporadic clusters, representing less than 0.1% of the total cell population.

Stage 2: Cultures in the First 3 Weeks After Implantation in Matrigel.

Clusters of beads with the mixed cell populations were placed in Matrigel (Collaborative Research) as described in Materials and Methods. This resulted in a series of cell migrations. Mesenchymal cells with stellate shape migrated out of the beads first at about day 4 to 5 and in many instances formed a mat surrounding the beads (Figure 5A).

Protrusions with rounded contours, appearing as buds, were seen extending randomly in all directions from the bead clusters at about day 7 to 10. Some of them (approximately 30%) appeared to contain ducts. The typical appearance of these cultures is shown in Figure 5B. Sections of these bud structures stained with hematoxylin and eosin are shown in Figure 6. The buds consisted primarily of hepatocytes arranged in acinar structures or in sheets. Electron microscopy (Figure 7) showed enhanced cytoplasmic differentiation of hepatocytes compared with cells in the roller bottle. Hepatocytes in the buds contained abundant lamellae of rough endoplasmic reticulum, glycogen, and

canaliculi with complete junctional complexes. The latter features are not seen in the hepatocytes before implantation in Matrigel. In most cultures, several long plates, 1 to 2 hepatocytes in width and 10 to 20 hepatocytes in length (Figure 8), were seen. These structures averaged about 20 to 30 per plate, with plates of different length extending

5 from most clusters. The plates typically developed into areas of the substratum that were free of other cell types. There were no visible nonparenchymal cells underlying or surrounding these plates. A typically demarcated and fully developed canalicular network was seen along the entire length of the plates. Many of these single plates contained ducts at the end. IL6 (10 ng/mL) added to the cultures augmented the number

10 of duct structures and caused formation of ducts along the plates or in the monolayer patches of hepatocytes. TGF- β 1 (at 0.5 ng/mL) inhibited formation of all structures that developed from epithelial cells (buds, plates, and ducts) though migration of the nonparenchymal cells was not inhibited. The full spectrum of changes was seen in the presence of HGF plus EGF. Cultures maintained in HGF or EGF alone showed fewer

15 and more limited changes per cluster compared with those with both growth factors. The extensive budding of the epithelial cells was associated with cell proliferation as judged by staining for PCNA. The numbers of labeled hepatocytes in the Matrigel ranged from 40% to 80% of epithelial cells per cluster, with considerable variation seen from one site to the next or among clusters. The BRdU labeling index, indicating active DNA

20 synthesis, varied from 10% to 15% per cluster. Desmin-positive cells were seen interspersed and surrounding the hepatocytes. Type IV collagen was seen often as a thin

rim surrounding acinar structures of hepatocytes. Slight staining was seen for type I and stronger staining for type III collagen (Figure 9).

Stage 3: Long-Term Cultures in Matrigel. Long-term follow-up showed that HGF or EGF added separately was not sufficient to maintain prolonged viability of the epithelial cells. By 3 months, no epithelial cells were present in cultures maintained in HGF or EGF alone, or in control cultures without the addition of growth factors. In cultures maintained with combined HGF plus EGF, large monolayer patches of hepatocytes ranging from 2 to 10 mm in diameter were seen (Figure 10). These structures appear at the rate of 2 to 4 patches per plate. These patches had a cyto-architecture of striking similarity to sections of the liver acinus. Single or double hepatocyte plates were seen extending in a linear or convoluted manner. Complete canalicular networks developed throughout the entire length of each of the plates. The plates were separated by spaces that, though resembling the sinusoidal spaces seen in the liver lobules, did not contain any cells. Occasional ducts were also present in random locations along the plate structures. Electron microscopy (Figure 11) showed typical hepatocyte morphology with most features typically present in hepatocytes, including glycogen, abundant rough endoplasmic reticulum, microbodies, and bile canaliculi with mature junctional complexes.

Gene Expression Changes in Cultures at Stages 1 and 2. The expression of several genes was examined in cultures at stages 1 and 2. Monolayers at stage 3 were not available in sufficient numbers for RNA preparation. Figure 12 compares expression of several genes in hepatocytes and nonparenchymal cells immediately after isolation

from liver, cells from roller bottle cultures at day 13, cells from roller bottle cultures at day 25, and cell-bead clusters at 12 days after implantation in Matrigel (Collaborative Research) (day 25 after cell isolation). The first and last lanes show expression of the same genes respectively in hepatocytes and the nonparenchymal cell fraction,

5 immediately after isolation from the rat liver. (several hepatocyte associated genes are expressed in this fraction as a result of contamination by small hepatocytes). Through Matrigel-enhanced expression of α -fetoprotein, cultures in the roller bottles and in Matrigel maintained high expression of albumin. EGF-receptor expression decreased in culture, whereas HGF-receptor expression was maintained in roller bottles and in

10 Matrigel, though Matrigel caused a decrease in c-met expression, CYPB1 expression decreased gradually in the roller bottle cultures but was restored after addition of Matrigel. TGF- β 1 expression, derived from the nonparenchymal cells present in the mixed cultures, was pronounced in the roller bottle cultures at stage 1 but suppressed by Matrigel in stage 2 cultures. The same was true for urokinase plasminogen activator and

15 its receptor urokinase plasminogen activator-R. Expression of transferrin and α -1 antitrypsin was also enhanced at stage 2. A separate study was conducted to evaluate induction of cytochrome P450 species in stage 1 cultures. Induction of cytochrome P450 species CYP1A, CYP3A, CYP2B1/2 was seen in response to 3' Methyl-cholanthrene, Dexamethasone, and Phenobarbital, respectively.

20 Figure 13A-C demonstrates induction of the cytochrome P450 species CYP3A (Figure 13A), CYP1A (Figure 13 B) and CYP2B1/2 (Figure 13C) by their characteristic inducers in day 35 cultures. The increase demonstrated by western

immunoblot. Dexamethasone, methylcholanthrene) and phenobarbital were the inducers used correspondingly. The activities of testosterone 6 β -hydroxylase (CYP3A dependent) and ethoxyresorufin O-deethylase (CYP1A dependent) were also measured in the same cultures. As demonstrated in Figure 14, more than 20-fold induction was seen in both cases by the characteristic inducers.

The present invention is not to be limited in scope by the specific embodiments described herein which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the claims. Various publications are cited herein, the contents of which are hereby incorporated, by reference, in their entireties.

WE CLAIM:

1 1. A method for generating a hepatic cell culture comprising co-
 2 culturing hepatocytes and nonparenchymal cells, in the presence of growth factors and a
 3 matrix coated with at least one biologically active molecule that promotes cell adhesion,
 4 proliferation or survival under conditions sufficient to allow for the proliferation of
 5 hepatocytes that retain hepatic function.

1 2. The method of claim 1 wherein the hepatocytes and
 2 nonparenchymal cells are derived from a liver tissue sample.

1 3. The method of claim 1 wherein the matrix is in the form of
 2 polystyrene beads.

1 4. The method of claim 1 wherein the matrix is coated with an
 2 extracellular matrix protein.

1 5. The method of claim 1 wherein the matrix is coated with type I
 2 collagen.

1 6. The method of claim 1 wherein the growth factor is epidermal
 2 growth factor.

1 7. The method of claim 1 wherein the growth factor is hepatocyte
2 growth factor.

1 8. A method for generating a three-dimensional hepatic cell culture
2 system comprising:
3 contacting a three-dimensional support matrix with a
4 hepatic cell culture comprising hepatocytes and
5 nonparenchymal cells bound to a matrix coated with at least
6 one biologically active molecule that promotes cell
7 adhesion, proliferation or survival;
8 under conditions sufficient to allow for the proliferation of the
9 hepatic cell culture to form a three-dimensional hepatic cell
10 structure.

1 9. The method of claim 8 wherein the hepatocytes and
2 nonparenchymal cells derived from a liver tissue sample.

1 10. The method of claim 8 wherein the matrix is in the form of a
2 biomatrix gel.

1 11. The method of claim 8 wherein the matrix is coated with an
2 extracellular matrix protein.

1 12. The method of claim 1 wherein the matrix is coated with type I
2 collagen.

1 13. The method of claim 8 wherein the matrix further comprises
2 growth factors incorporated into said matrix.

1 14. A population of matrix/hepatic cell clusters comprising
2 hepatocytes and nonparenchymal cells associated with a matrix coated with at least one
3 biologically active molecule that promotes cell adhesion, proliferation or survival.

1 15. A composition comprising matrix/hepatic cell clusters grown on a
2 three-dimensional support matrix wherein said matrix hepatic cell clusters comprising
3 hepatocytes and nonparenchymal cells bound to a matrix coated with at least one
4 biologically active molecule that promotes cell adhesion, proliferation or survival.

1 16. A three-dimensional tissue culture matrix prepared by a process
2 comprising:
3 contacting a three-dimensional support matrix with a
4 hepatic cell culture comprising hepatocytes and

5 nonparenchymal cells bound to a matrix coated with at least
6 one biologically active molecule that promotes cell
7 adhesion, proliferation or survival;
8 under conditions sufficient to allow for the proliferation of the
9 hepatic cell culture.

- 1 17. A method for providing hepatic function in a subject having a liver
2 disorder comprising administering to said subject a three-
3 dimensional tissue culture matrix prepared by a process
4 comprising:
5 contacting a three-dimensional support matrix with a
6 hepatic cell culture comprising hepatocytes and
7 nonparenchymal cells bound to a matrix coated with at least
8 one biologically active molecule that promotes cell
9 adhesion, proliferation or survival, under conditions
10 sufficient to allow for the proliferation of the hepatic cell
11 culture;
12 in an amount sufficient to reduce the symptoms associated with the
13 liver disorder.

- 1 18. The method of claim 17 wherein the liver disorder is cirrhosis of
2 the liver.

1

19. The method of claim 18 wherein the liver disorder is hepatitis.

Accepted for publication

Figure 1A






Figure 1B




664027 2865460

Figure 2




664027 2365460

Figure 3A-C



66402T 2965460

Figure 5A-B



0945953-120799
662027-2965460

A32515
(Sheet 6 of 16)

Figure 6



004533-120799
66202T-2365460

A32515
(Sheet 7 of 16)

Figure 7A



664027-2565460

Figure 7B



09455933-120793
667027-2565460

A32515
(Sheet 9 of 16)


Figure 8



09453930-130760

A32515
(Sheet 10 of 16)


Figure 9A-D



667021 2565460

A32515
(Sheet II of 16)

Figure 10A-B



66202T 2565960

Figure 11A



662021 2565460

Figure 11B



66702T 25695460

Figure 12





Figure 13 A-C


CYP3A

A.




CYP1A

B.



CYP2B1/2

C.



A32515
(Sheet 1b of 14)





Figure 14

**COMBINED DECLARATION
AND POWER OF ATTORNEY**

(Original, Design, National Stage of PCT, Divisional, Continuation or C-I-P Application)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

“A NOVEL LONG-TERM THREE DIMENSIONAL TISSUE CULTURE SYSTEM”

This declaration is of the following type:

- ☒ original
- ☐ design
- ☐ national stage of PCT.
- ☐ divisional
- ☐ continuation
- ☐ continuation-in-part (C-I-P)

The specification of which: *(complete (a), (b), or (c))*

- (a) ☒ is attached hereto.
- (b) ☐ was filed on as Application Serial No. and was amended on *(if applicable)*.
- (c) ☐ was described and claimed in PCT International Application No. filed on and was amended on *(if applicable)*.

Acknowledgement of Review of Papers and Duty of Candor

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of the subject matter claimed in this application in accordance with Title 37, Code of Federal Regulations § 1.56.

☐ In compliance with this duty there is attached an information disclosure statement. 37 CFR 1.98.

Priority Claim

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed

(complete (d) or (e))

- (d) ☒ no such applications have been filed.
- (e) ☐ such applications have been filed as follows:

PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
COUNTRY	APPLICATION NO.	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
			PRIORITY CLAIMED UNDER 35 USC 119 <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
			<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
			<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
ALL FOREIGN APPLICATION[S], IF ANY, FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
			<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
			<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
			<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>

Claim for Benefit of Prior U.S. Provisional Application(s)

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Provisional Application Number	Filing Date

Claim for Benefit of Earlier U.S./PCT Application(s) under 35 U.S.C. 120

(complete this part only if this is a divisional, continuation or C-I-P application)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information as defined in Title 37, Code of Federal Regulations, § 1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

Power of Attorney

As a named inventor, I hereby appoint Dana M. Raymond, Reg. No. 18,540; Frederick C. Carver, Reg. No. 17,021; Francis J. Hone, Reg. No. 18,662; Joseph D. Garon, Reg. No. 20,420; Arthur S. Tenser, Reg. No. 18,839; Ronald B. Hildreth, Reg. No. 19,498; Thomas R. Nesbitt, Jr., Reg. No. 22,075; Robert Neuner, Reg. No. 24,316; Richard G. Berkley, Reg. No. 25,465; Richard S. Clark, Reg. No. 26,154; Bradley B. Geist, Reg. No. 27,551; James J. Maune, Reg. No. 26,946; John D. Murnane, Reg. No. 29,836; Henry Tang, Reg. No. 29,705; Robert C. Scheinfeld, Reg. No. 31,300; John A. Fogarty, Jr., Reg. No. 22,348; Louis S. Sorell, Reg. No. 32,439; Rochelle K. Seide Reg. No. 32,300; Gary M. Butter, Reg. No. 33,841; Marta E. Delsignore, Reg. No. 32,689; and Lisa B. Kole, Reg. No. 35,225 of the firm of BAKER & BOTTS, L.L.P., with offices at 30 Rockefeller Plaza, New York, New York 10112, as attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith

SEND CORRESPONDENCE TO: BAKER & BOTTS, L.L.P. 30 ROCKEFELLER PLAZA, NEW YORK, N.Y. 10112 CUSTOMER NUMBER: 21003	DIRECT TELEPHONE CALLS TO: BAKER & BOTTS, L.L.P. (212) 705-5000
--	---

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge

that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	LAST NAME Michalopoulos	FIRST NAME George	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY Bethel	STATE or FOREIGN COUNTRY PA	COUNTRY OF CITIZENSHIP United States	
POST OFFICE ADDRESS	POST OFFICE ADDRESS 35 Highland Road, Apt. #6207	CITY Bethel	STATE or COUNTRY PA	ZIP CODE 15102
DATE	SIGNATURE OF INVENTOR			
FULL NAME OF SECOND JOINT INVENTOR, IF ANY	LAST NAME Bowen	FIRST NAME William	MIDDLE NAME C.	
RESIDENCE & CITIZENSHIP	CITY White Oak	STATE or FOREIGN COUNTRY PA	COUNTRY OF CITIZENSHIP United States	
POST OFFICE ADDRESS	POST OFFICE ADDRESS 1908 Dearborn Drive	CITY White Oak	STATE or COUNTRY PA	ZIP CODE 15131
DATE	SIGNATURE OF INVENTOR			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			